Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with COVID-19
Xin Zhou,Yongle Li,Qing Yang
DOI: https://doi.org/10.1161/circulationaha.120.046988
IF: 37.8
2020-01-01
Circulation
Abstract:HomeCirculationVol. 141, No. 22Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With COVID-19 Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBAntiplatelet Therapy After Percutaneous Coronary Intervention in Patients With COVID-19Implications From Clinical Features to Pathologic Findings Xin Zhou, Yongle Li and Qing Yang Xin ZhouXin Zhou Department of Cardiology, Tianjin Medical University General Hospital, China. , Yongle LiYongle Li Department of Cardiology, Tianjin Medical University General Hospital, China. and Qing YangQing Yang Qing Yang, MD, PhD, Department of Cardiology, Tianjin Medical University General Hospital, 154, Anshan Road, Heping District, Tianjin 300052, China. Email E-mail Address: [email protected] Department of Cardiology, Tianjin Medical University General Hospital, China. Originally published16 Apr 2020https://doi.org/10.1161/CIRCULATIONAHA.120.046988Circulation. 2020;141:1736–1738Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: April 16, 2020: Ahead of Print On March 11, 2020, the World Health Organization officially declared the novel coronavirus disease 2019 (COVID-19) a global pandemic. Considering that ≈5 million percutaneous coronary interventions (PCIs) are performed worldwide annually, safety concerns exist about the effect of dual antiplatelet therapy (DAPT) on bleeding complications, especially the risk for diffuse alveolar hemorrhage, among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).SARS-CoV-2 and SARS-CoV have a shared cellular target: angiotensin-converting enzyme 2. When comparing the clinical manifestations of infections with these viruses, we found that thrombocytopenia (platelet count <150 000/μL), prolonged thrombin time, and elevated D-dimer levels were observed frequently in both,1,2 suggestive of high likelihood of disseminated intravascular coagulation or pre–disseminated intravascular coagulation. Diffuse alveolar hemorrhage was reported as a common finding in lung pathology in severe acute respiratory syndrome and COVID-19.3,4Although incompletely understood, previous findings from influenza pneumonia revealed a mechanistic link between virus infection and the risk for diffuse alveolar hemorrhage (summarized in the Figure), which starts with virus replication and dissemination, followed by alveolar endothelial dysfunction, platelet activation, generation of neutrophil–platelet aggregates, neutrophil migration, and fibrin and microthrombus formation; if left uncontrolled, these alterations would trigger secondary fibrinolysis, coagulation factors depletion, and consequently disseminated intravascular coagulation and diffuse alveolar hemorrhage. Diffuse alveolar hemorrhage refers to a distinct form of life-threatening pulmonary hemorrhage that originates from pulmonary microcirculation (alveolar arterioles, capillaries, and venules) and should be distinguished from other causes of pulmonary hemorrhage caused by localized abnormalities (bronchiectasis, malignancy, and tuberculosis). Although alveolar hemorrhage can be localized, there are generally multiple areas of involvement; therefore, the term "diffuse alveolar hemorrhage" is preferred. In the rapid progressive and life-threatening form of viral pneumonia, the underlying pathologic process is often diffuse alveolar hemorrhage. Collectively, the pathologic and clinical features of COVID-19 are mechanistically linked to high risk for disseminated intravascular coagulation and propensity for diffuse alveolar hemorrhage.Download figureDownload PowerPointFigure. The potential pathophysiologic evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung tissue and implications for antiplatelet therapy. Early antiplatelet therapy, especially P2Y12 antagonists, may be beneficial because of their inhibitory effects on platelet activation and generation of neutrophil–platelet aggregates, key mechanisms in thrombus formation and pulmonary neutrophil recruitment.In addition to thrombosis and hemostasis, emerging evidence supports a putative role of platelets in the host defense against infections, which adds a greater layer of complexity in evaluating the role of antiplatelet therapy in the setting of viral pneumonia. The following 3 issues should be taken into account when interpreting the effect of antiplatelet therapy on disease progression. First, the timing of administration is important. As summarized in the Figure, in the early phase of infection, platelet inhibition may reduce intravascular fibrin and thrombus formation, thereby preventing the ensuing consequences. Aspirin use before hospitalization, but not after hospitalization, was associated with lower risk of developing severe acute respiratory distress syndrome and mortality in patients with community-acquired pneumonia. Second, the choice of oral P2Y12 inhibitors deserves consideration. Although all P2Y12 inhibitors reduce platelet–leukocyte aggregates and platelet-derived proinflammatory cytokines from α-granules, ticagrelor is unique in having the only well-documented additional target of inhibition ENT1 (equilibrative nucleoside transporter 1), contributing to inhibition of cellular adenosine uptake. Therefore, ticagrelor confers more potent anti-inflammatory properties by inhibiting platelet P2Y12 receptor and ENT1. The XANTHIPPE trial (Targeting Platelet–Leukocyte Aggregates in Pneumonia With Ticagrelor; URL:https://www.clinicaltrials.gov; Unique identifier: NCT01883869), as well as post hoc analyses of the PLATO study (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome; URL:https://www.clinicaltrials.gov; Unique identifier: NCT00391872) and basic research, provide evidence demonstrating the clinical benefit of ticagrelor in the management of pneumonia by preventing the complications of sepsis and reducing lung injury. Third, circulating platelet counts are important. Both primary thrombocytopenia (immune thrombocytopenia) and secondary thrombocytopenia (enhanced consumption) are associated with increased risk of infection (including pneumonia) and worsened clinical outcomes associated with acute respiratory distress syndrome. Thrombocytopenia leads to loss of the ability to deposit fibrinogen and to seal the damaged pulmonary vasculature. Expert consensus warrants taking proactive measures or stopping antiplatelet therapy in patients with a platelet count <100 000/μL or <50 000/μL, respectively.Emerging evidence suggests DAPT as an important aggravating factor for diffuse alveolar hemorrhage, which could be mistaken as pneumonia initially because of similarities in clinical manifestations (ie, coughing, radiographic evidence of mild infiltration, and fever). Given the high bleeding risk in patients with COVID-19 after PCI, shorter-duration DAPT may be beneficial in this population.To counterbalance the increased bleeding risk associated with DAPT, emerging findings from large randomized controlled trials provide evidence supporting a net benefit of aspirin-free strategies after PCI for patients at low, intermediate, and high risk for both ischemia and bleeding, which is mainly driven by reduction in bleeding events. This strategy reduces the duration of aspirin use (1 to 3 months) and allows for more prolonged use of potent P2Y12 inhibitors. When faced with the challenge of the COVID-19 pandemic with insufficient evidence regarding appropriate antithrombotic regimens for patients after PCI, we must extrapolate information from related clinical scenarios to assist in decision making. Among patients on DAPT, maintaining P2Y12 inhibitor monotherapy (preferably ticagrelor) may be scientifically reasonable for ≥3 months after PCI. DAPT should not be discontinued <3 months after PCI. Considering recent experience from China demonstrating the effectiveness of low-molecular-weight heparin in reversing disseminated intravascular coagulation in COVID-19,5 the International Society of Thrombosis and Hemostasis disseminated intravascular coagulation scoring system and platelet counting should be performed daily or more frequently to identify patients who would benefit from early low-molecular-weight heparin administration or from discontinuation of P2Y12 antagonists because of clinically meaningful thrombocytopenia. The trade-off between ischemia and bleeding may be challenging when patients take an oral P2Y12 inhibitor concomitantly with an indication for low-molecular-weight heparin prophylaxis. An alternative approach in this setting would involve using an intravenous P2Y12 inhibitor such as cangrelor as bridge therapy.The COVID-19 pandemic presents a unique opportunity to study key questions concerning the preventive, therapeutic, or aggravating effects of antiplatelet therapy on viral pneumonia on the basis of nonrandomized real-world data. Clinicians must be cognizant of the effects of antiplatelet therapy in patients with COVID-19.AcknowledgmentsThe authors thank Drs Haonan Sun, Zhijia Wang, Hangkuan Liu, Yifan Guo, Chunpo Liang, and Chengcheng Wu for literature search and suggestions.Sources of FundingThis work was supported by the Tianjin Municipal Science and Technology Commission (18ZXZNSY00290) and the National Natural Science Foundation of China (81970304).DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.https://www.ahajournals.org/journal/circQing Yang, MD, PhD, Department of Cardiology, Tianjin Medical University General Hospital, 154, Anshan Road, Heping District, Tianjin 300052, China. Email cardio-yq@tmu.edu.cnReferences1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al; for China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China [published online February 28, 2020].N Engl J Med. doi: 10.1056/NEJMoa2002032. https://www.nejm.org/doi/10.1056/NEJMoa2002032Google Scholar2. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong.N Engl J Med. 2003; 348:1986–1994. doi: 10.1056/NEJMoa030685CrossrefMedlineGoogle Scholar3. Lang ZW, Zhang LJ, Zhang SJ, Meng X, Li JQ, Song CZ, Sun L, Zhou YS, Dwyer DE. A clinicopathological study of three cases of severe acute respiratory syndrome (SARS).Pathology. 2003; 35:526–531. doi: 10.1080/00313020310001619118CrossrefMedlineGoogle Scholar4. Luo W, Yu H, Guo J, Li X, Sun Y, Li J, Liu L. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19).Preprints. 2020;2020020407.Google Scholar5. Wang YD, Zhang SP, Wei QZ, Zhao MM, Mei H, Zhang ZL, Hu Y. [COVID-19 complicated with DIC: 2 case reports and literature review; published online March 5, 2020.]Zhonghua Xue Ye Xue Za Zhi. doi: 10.3760/cma.j.issn.0253-2727.2020.0001. http://rs.yiigle.com/CN121090202003/1190310.htmGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Antoniello A, Brophy A and Opsha Y (2021) Evaluation of Hospitalized Patient Outcomes in COVID-19 Infection for Continued versus Discontinued Use of Preadmission Antiplatelet Regimen, Journal of Pharmacy Practice, 10.1177/08971900211053294, 36:3, (508-513), Online publication date: 1-Jun-2023. Potpara T, Angiolillo D, Bikdeli B, Capodanno D, Cole O, Yataco A, Dan G, Harrison S, Iaccarino J, Moores L, Ntaios G and Lip G (2023) Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19, CHEST, 10.1016/j.chest.2023.06.032, Online publication date: 1-Jun-2023. Nasab E, Aghajani H, Makoei R and Athari S (2023) COVID-19's immuno-pathology and cardiovascular diseases, Journal of Investigative Medicine, 10.1177/10815589221141841, 71:2, (71-80), Online publication date: 1-Feb-2023. Utomo N and Iswarini A (2022) Impaired olfaction post-coronavirus disease 2019: a systematic review of smell recovery predictive factors, The Egyptian Journal of Otolaryngology, 10.1186/s43163-022-00271-5, 38:1, Online publication date: 1-Dec-2022. Mohammed A, Abo-Idrees M, Makki A, Ibraheem W and Alzain A (2022) Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics, Structural Chemistry, 10.1007/s11224-022-01999-9, 33:5, (1553-1567), Online publication date: 1-Oct-2022. Pillay-Fuentes Lorente V, Van Rensburg R, Moolla M, McCaul M, Parker A, Taljaard J, Reuter H and Decloedt E (2022) Bleeding and thrombosis outcomes in hospitalised COVID-19 patients on low-molecular-weight heparin and antiplatelet therapy, South African Medical Journal, 10.7196/SAMJ.2022.v112i7.16434 Zhu A, Real F, Capron C, Rosenberg A, Silvin A, Dunsmore G, Zhu J, Cottoignies-Callamarte A, Massé J, Moine P, Bessis S, Godement M, Geri G, Chiche J, Valdebenito S, Belouzard S, Dubuisson J, Lorin de la Grandmaison G, Chevret S, Ginhoux F, Eugenin E, Annane D, Bordé E and Bomsel M (2022) Infection of lung megakaryocytes and platelets by SARS-CoV-2 anticipate fatal COVID-19, Cellular and Molecular Life Sciences, 10.1007/s00018-022-04318-x, 79:7, Online publication date: 1-Jul-2022. Malik M, Amer S, Merrell E, Russo R, Riley J, Scro A, James E, Anuforo A, Adhikari S, Siciliano R, Chebaya P, Darling E, Kuhn M, Nieman G, Shawkat A and Aiash H (2022) Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID‐19, analytical cross‐sectional study, Health Science Reports, 10.1002/hsr2.699, 5:4, Online publication date: 1-Jul-2022. Lasica R, Djukanovic L, Mrdovic I, Savic L, Ristic A, Zdravkovic M, Simic D, Krljanac G, Popovic D, Simeunovic D, Rajic D and Asanin M (2022) Acute Coronary Syndrome in the COVID-19 Era—Differences and Dilemmas Compared to the Pre-COVID-19 Era, Journal of Clinical Medicine, 10.3390/jcm11113024, 11:11, (3024) Santoro F, Nuñez-Gil I, Vitale E, Viana-Llamas M, Reche-Martinez B, Romero-Pareja R, Feltez Guzman G, Fernandez Rozas I, Uribarri A, Becerra-Muñoz V, Alfonso-Rodriguez E, Garcia-Aguado M, Huang J, Ortega-Armas M, Garcia Prieto J, Corral Rubio E, Ugo F, Bianco M, Mulet A, Raposeiras-Roubin S, Jativa Mendez J, Espejo Paeres C, Albarrán A, Marín F, Guerra F, Akin I, Cortese B, Ramakrishna H, Macaya C, Fernandez-Ortiz A and Brunetti N (2021) Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry, Heart, 10.1136/heartjnl-2021-319552, 108:2, (130-136), Online publication date: 1-Jan-2022. Simova I, Hristova D, Tzanovska H, Nikolov D, Iakova D, Ivanova A, Pintova M, Pavlov P, Matkov O, Samardjiev T, Kornovski V, Krasnaliev J, Kundurzhiev T, Dimitrov N and Vekov T (2021) Post COVID-19 Conditions and the Cardiovascular System Fighting the COVID-19 Pandemic, 10.5772/intechopen.99197 Pratomo I, Noor D, Kusmardi K, Rukmana A, Paramita R, Erlina L, Fadilah F, Gayatri A, Fitriani M, Purnomo T, Ariane A, Heryanto R, Tedjo A and Moshage H (2021) Xanthine Oxidase-Induced Inflammatory Responses in Respiratory Epithelial Cells: A Review in Immunopathology of COVID-19, International Journal of Inflammation, 10.1155/2021/1653392, 2021, (1-10), Online publication date: 5-Aug-2021. Abdelwahab H, Shaltout S, Sayed Ahmed H, Fouad A, Merrell E, Riley J, Salama R, Abdelrahman A, Darling E, Fadel G, Elfar M, Sabry K, Shah J, Amin H, Nieman G, Mishriky A and Aiash H (2021) Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study, Clinical Drug Investigation, 10.1007/s40261-021-01061-2, 41:8, (723-732), Online publication date: 1-Aug-2021. Martha J, Pranata R, Lim M, Wibowo A and Akbar M (2021) Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates, International Journal of Infectious Diseases, 10.1016/j.ijid.2021.05.016, 108, (6-12), Online publication date: 1-Jul-2021. Sayed Ahmed H, Merrell E, Ismail M, Joudeh A, Riley J, Shawkat A, Habeb H, Darling E, Goweda R, Shehata M, Amin H, Nieman G and Aiash H (2021) Rationales and uncertainties for aspirin use in COVID-19: a narrative review, Family Medicine and Community Health, 10.1136/fmch-2020-000741, 9:2, (e000741), Online publication date: 1-Apr-2021. Gurovich A, Tiwari S, Kehl S, Umucu E and Peñailillo L (2020) A Novel "Eccentric" Therapeutic Approach for Individuals Recovering From COVID-19, Cardiopulmonary Physical Therapy Journal, 10.1097/CPT.0000000000000163, 32:1, (S15-S21), Online publication date: 1-Apr-2021. Samimi Ardestani S, Mohammadi Ardehali M, Rabbani Anari M, Rahmaty B, Erfanian R, Akbari M, Motedayen Z, Samimi Niya F, Aminloo R, Farahbakhsh F, Hosseininasab A, Hassanlouei B, Rezaian N and Mokhtari Z (2020) The coronavirus disease 2019: the prevalence, prognosis, and recovery from olfactory dysfunction (OD), Acta Oto-Laryngologica, 10.1080/00016489.2020.1836397, 141:2, (171-180), Online publication date: 1-Feb-2021. Liu H, Wang Z, Sun H, Teng T, Li Y, Zhou X and Yang Q (2021) Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.599334, 7 Salukhov V, Gulyaev N and Dorokhina E (2021) Assessment of systemic inflammatory reactions and coagulopathy against the background of hormonal therapy in covid-associated lung damage, Meditsinskiy sovet = Medical Council, 10.21518/2079-701X-2020-21-230-237:21, (230-237) Iba T, Levy J, Connors J, Warkentin T, Thachil J and Levi M (2020) The unique characteristics of COVID-19 coagulopathy, Critical Care, 10.1186/s13054-020-03077-0, 24:1, Online publication date: 1-Dec-2020. Dehghani T and Panitch A (2020) Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle, Open Biology, 10.1098/rsob.200161, 10:10, Online publication date: 1-Oct-2020. Frazer J and Tyrynis Everden A (2020) Emerging patterns of hypercoagulability associated with critical COVID-19: A review, Trends in Anaesthesia and Critical Care, 10.1016/j.tacc.2020.07.004, 34, (4-13), Online publication date: 1-Oct-2020. Soeiro A, Leal T, Pereira M, Lima E, Figueiredo A, Petriz J, Precoma D and Serrano C (2020)(2020)(2020)(2020) Posicionamento sobre Uso de Antiplaquetários e Anticoagulantes nos Pacientes Infectados pelo Novo Coronavírus (COVID-19) – 2020, Arquivos Brasileiros de Cardiologia, 10.36660/abc.20200424, 115:2, (292-301), Online publication date: 19-Aug-2020., Online publication date: 19-Aug-2020., Online publication date: 1-Aug-2020., Online publication date: 1-Aug-2020. Amgalan A and Othman M (2020) Hemostatic laboratory derangements in COVID-19 with a focus on platelet count, Platelets, 10.1080/09537104.2020.1768523, 31:6, (740-745), Online publication date: 17-Aug-2020. Su Y, Kuo M, Lin T, Chien C, Yang Y, Chou S and Leu H (2020) Cardiovascular manifestation and treatment in COVID-19, Journal of the Chinese Medical Association, 10.1097/JCMA.0000000000000352, 83:8, (704-709), Online publication date: 1-Aug-2020. Sattar Y, Ullah W, Rauf H, Virk H, Yadav S, Chowdhury M, Connerney M, Mamtani S, Pahuja M, Patel R, Mir T, Almas T, Moussa Pacha H and Chadi Alraies M (2020) COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management, IJC Heart & Vasculature, 10.1016/j.ijcha.2020.100589, 29, (100589), Online publication date: 1-Aug-2020. Chen X, Zhao X, Cooper M and Ma P (2020) The Roles of GRKs in Hemostasis and Thrombosis, International Journal of Molecular Sciences, 10.3390/ijms21155345, 21:15, (5345) Marchandot B, Sattler L, Jesel L, Matsushita K, Schini-Kerth V, Grunebaum L and Morel O (2020) COVID-19 Related Coagulopathy: A Distinct Entity?, Journal of Clinical Medicine, 10.3390/jcm9061651, 9:6, (1651) Mahajan K and Batra A (2020) Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era, Indian Heart Journal, 10.1016/j.ihj.2020.05.009, 72:3, (209-211), Online publication date: 1-May-2020. Al-Kuraishy H, Al-Gareeb A, Al-Niemi M, Al-Buhadily A, Al-Harchan N and Lugnier C (2020) COVID-19 and phosphodiesterase enzyme type 5 inhibitors, Journal of Microscopy and Ultrastructure, 10.4103/JMAU.JMAU_63_20, 8:4, (141), . Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J, Wani F, Kumar A, Vallabhaneni S and Khan M (2020) COVID-19 and Hypercoagulability: A Review, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029620962853, 26, (107602962096285), Online publication date: 1-Jan-2020. June 2, 2020Vol 141, Issue 22 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.046988PMID: 32298134 Originally publishedApril 16, 2020 KeywordscoronavirusCOVID-19PDF download Advertisement SubjectsCoronary Artery DiseasePercutaneous Coronary InterventionPharmacology